ResMed (RMD)
(Delayed Data from NYSE)
$203.15 USD
-0.73 (-0.36%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $203.00 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Income Statements
Fiscal Year end for ResMed Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | |
---|---|---|---|---|---|
Sales | NA | 4,223 | 3,578 | 3,197 | 2,957 |
Cost Of Goods | NA | 1,867 | 1,554 | 1,358 | 1,239 |
Gross Profit | NA | 2,356 | 2,024 | 1,839 | 1,718 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 1,224 | 1,024 | 935 | 908 |
Income After Depreciation & Amortization | 0 | 1,132 | 1,000 | 904 | 810 |
Non-Operating Income | NA | 17 | -17 | 4 | -36 |
Interest Expense | NA | 47 | 22 | 24 | 40 |
Pretax Income | NA | 1,102 | 960 | 884 | 733 |
Income Taxes | NA | 204 | 181 | 409 | 111 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 898 | 779 | 475 | 622 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 898 | 779 | 475 | 622 |
Depreciation Footnote | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 1,329 | 1,194 | 1,095 | 991 |
Depreciation & Amortization (Cash Flow) | NA | 198 | 194 | 192 | 181 |
Income After Depreciation & Amortization | 0 | 1,132 | 1,000 | 904 | 810 |
Earnings Per Share Data | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Average Shares | NA | 147.46 | 147.04 | 146.45 | 145.65 |
Diluted EPS Before Non-Recurring Items | NA | 6.44 | 5.79 | 5.33 | 4.76 |
Diluted Net EPS (GAAP) | NA | 6.09 | 5.30 | 3.24 | 4.27 |
Fiscal Year end for ResMed Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 1,196.98 | 1,162.80 | 1,102.32 | 1,122.06 |
Cost Of Goods | NA | 504.20 | 515.87 | 502.26 | 504.67 |
Gross Profit | NA | 692.78 | 646.93 | 600.06 | 617.39 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 318.19 | 371.84 | 311.06 | 332.94 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 374.59 | 275.09 | 289.00 | 284.45 |
Non-Operating Income | NA | 11.86 | -1.84 | -1.85 | 16.48 |
Interest Expense | NA | 11.03 | 13.81 | 14.96 | 14.94 |
Pretax Income | NA | 375.42 | 259.45 | 272.19 | 276.80 |
Income Taxes | NA | 74.93 | 50.65 | 52.77 | 47.14 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 300.49 | 208.80 | 219.42 | 229.66 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 300.49 | 208.80 | 219.42 | 229.66 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 147.45 | 147.55 | 147.49 | 147.55 |
Diluted EPS Before Non-Recurring Items | NA | 2.13 | 1.88 | 1.64 | 1.60 |
Diluted Net EPS (GAAP) | NA | 2.04 | 1.42 | 1.49 | 1.55 |